COLL:NSD-Collegium Pharmaceutical, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 25.25

Change

+0.29 (+1.16)%

Market Cap

USD 0.88B

Volume

0.21M

Avg Analyst Target

USD 34.00 (+34.65%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

N/A

USD8.59B 30.73 11.86
CGC Canopy Growth Corporation

-0.03 (-0.16%)

USD7.46B N/A N/A
APHA Tilray, Inc

N/A

USD6.86B 60.60 454.68
TLRY Tilray, Inc

-0.36 (-2.46%)

USD6.56B N/A N/A
MNTA Momenta Pharmaceuticals, Inc

N/A

USD6.24B N/A N/A
CRON Cronos Group Inc

+0.06 (+0.82%)

USD2.75B 37.00 N/A
PCRX Pacira BioSciences, Inc

+1.57 (+2.65%)

USD2.60B 17.73 37.25
IRWD Ironwood Pharmaceuticals, Inc

-0.27 (-2.03%)

USD2.15B 14.93 12.02
ORGO Organogenesis Holdings Inc

+0.11 (+0.75%)

USD1.97B 41.46 30.47
SNDL Sundial Growers Inc

N/A

USD1.53B -99,999.99 N/A

ETFs Containing COLL

Symbol Name Weight Mer Price(Change) Market Cap
BUY USCF SummerHaven SHPEI In.. 0.00 % 0.80 %

N/A

USD0.81M

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 26.06% 78% C+ 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.06% 78% C+ 74% C
Trailing 12 Months  
Capital Gain 51.56% 83% B 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 51.56% 83% B 66% D
Trailing 5 Years  
Capital Gain 110.59% 88% B+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 110.59% 88% B+ 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 23.81% 78% C+ 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.81% 78% C+ 70% C-
Risk Return Profile  
Volatility (Standard Deviation) 51.63% 47% F 35% F
Risk Adjusted Return 46.11% 92% A- 64% D
Market Capitalization 0.88B 79% C+ 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 21.13 50% F 44% F
Price/Book Ratio 5.16 32% F 29% F
Price / Cash Flow Ratio 9.34 21% F 39% F
EV/EBITDA 7.03 74% C 77% C+
Management Effectiveness  
Return on Equity 26.98% 94% A 92% A-
Return on Invested Capital 20.44% 92% A- 90% A-
Return on Assets 7.06% 95% A 88% B+
Debt to Equity Ratio 112.67% 22% F 18% F
Technical Ratios  
Short Ratio 18.04 3% F 1% F
Short Percent 14.07% 21% F 12% F
Beta 0.95 73% C 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.